**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/118

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | TENOFOVIR DISOPROXIL FUMARATE/ LAMIVUDINE/ EFAVIRENZ TABLETS 300 mg/300 mg /600 mg | | **REF. NO: NDQB201608061** |
| **DATE RECEIVED:** 2016-08-04 | **LABEL CLAIM:** | Each film coated tablet contains Tenofovir Disoproxil Fumarate 300 mg, Lamivudine 300 mg & Efavirenz 600 mg tablets. | |
| **BATCH NO.:** 3054981 | **PRESENTATION:** | Off white coloured, caplet shaped, biconvex faced tablets, embossed 'M 152' on one face and plain on the other, 30 tablets packed in a white plastic multi-dose container in a unit box. | |
| **MFG. DATE:** Jun. 2016 | **MANUFACTURER:** | MYLAN Laboratories Limited. | |
| **EXP. DATE:**  May 2019 | **ADDRESS:** | H-12 & H-13, MIDC, Waluj, Aurangabad - 431136, Maharashtra, INDIA | |
| **CLIENT REF NO:** | **CLIENT:** | Kenya Medical Supplies Authority, P.O. Box 47715 - 00100, Nairobi, Kenya. | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In - house Method | RT of the major peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 8.6,17.0 & 23.4 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In - house Method | No tablet less than 80% [n=6] | Efavirenz Average = 103% Range | **COMPLIES** |
| **Dissolution** |  |  | No tablet less than 85% [n=6] | 102 - 103% (RSD=0.2%, n=6) |  |
| **Dissolution** |  |  |  | Lamivudine Average = 103% Range |  |
| **Dissolution** |  |  |  | 102.6 - 103.0% (RSD=0.2%, n=6) |  |
| **Dissolution** |  |  |  | Tenofovir Disoproxil Fumarate Average = 98% Range |  |
| **Dissolution** |  |  |  | 97.8 - 98.3% (RSD=0.2%, n=6) |  |
| **Assay** | HPLC | Adopted In - house Method | 90.0 â€“ 110.0% | Efavirenz 96.1% (RSD=0.2%, n=9) | **COMPLIES** |
| **Assay** |  |  |  | Lamivudine 95.1% (RSD=0.6%, n=9) |  |
| **Assay** |  |  |  | Tenofovir Disoproxil Fumarate 99.7% (RSD=1.8%, n=6) |  |

**CONCLUSION:** The sample complies with the specifications for the test performed

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | DR ERIC MUTUA | .......................................................... | DATE: 08-04-2016 |
| **ANALYST:** | DR MATHAYO KWENA | .......................................................... | DATE: 09-01-2016 |
| **ANALYST:** | ERNEST MBAE | .......................................................... | DATE: 09-27-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 09-29-2016 |